is a Japanese-speaking patent attorney for Finnegan, with a Ph.D. in cell & molecular biology, I focus on patent litigation, prosecution, PTO trials, and strategic counseling in the fields of biologics and biosimilars, biotechnology, chemicals, and pharmaceuticals. I’ve practiced IP law in both DC and Manhattan, where I’ve dealt with all facets of Japanese-language e-discovery, assisted with pretrial strategic decision-making, shepherded numerous Japanese patent applications through US prosecution, crafted technology tutorials, built dossiers of potential expert witnesses in the field of biomedical sciences, and the like.
The current extraterritorial reach of U.S. trade secret law may seem ironic given trade secret law’s “local” roots. In the United States, common law trade secret principles emerged through a diverse patchwork of state court decisions addressing local commercial disputes. These local common law principles were first distilled in the Restatement of Torts and the Restatement of Unfair Competition and then codified in the Uniform Trade Secrets Act in 1979. Underscoring the local prerogative of trade secret law, state legislatures modified and tailored the Uniform Trade Secrets Act to reflect their state-specific concerns and needs. For many years, despite a push for national uniformity, a number of states chose not to adopt a statutory scheme at all (some still haven’t).